We are a late-stage biotechnology company pioneering the development of a novel class of TCR (T cell receptor) bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging our proprietary, flexible, off-the-shelf ImmTAX platform, we are developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. To date, we have dosed over 600 cancer patients with our ImmTAX product candidates, which we believe is the largest clinical data set of any bispecific in a solid tumor and any TCR therapeutic.  Our clinical programs are being conducted with patients with a broad range of cancers, including lung, bladder, gastric, head and neck and ovarian, among others.

Our most advanced oncology therapeutic candidate, tebentafusp, has demonstrated superior overall survival benefit as a monotherapy in a randomized Phase 3 clinical trial in previously untreated metastatic uveal melanoma (a cancer of the iris of the eye), a cancer that has historically proven to be insensitive to other immunotherapies. 

(Note: Immunocore priced its upsized IPO on Feb. 4, 2021, of 9.94 million American Depositary Shares (ADS) at $26 per ADS – up from 8.33 million shares at a $23-to-$25 price range – to raise $258.3 million.)